Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)

NCT05785832 is registered in ClinicalTrials.gov with Tandem Diabetes Care, Inc. as lead sponsor.

NCT NCT05785832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05785832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)
Lead sponsor
Tandem Diabetes Care, Inc.
Phase
Not applicable
Overall status
Completed
Start date
June 1, 2023
Completion date
September 24, 2024
Enrollment
319 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes treated with insulin